Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 7/20 | 0.33 |
| ▸ | AKT1 | P31749 | 2/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1285366 | 0.86 | CTSL (0.35) | PDE2ACYP17A1PPARGAKT1ROCK2 | |
| SCHEMBL1285369 | 0.86 | CTSL (0.35) | PDE2ACYP17A1PPARGAKT1ROCK2 | |
| SCHEMBL1643661 | 0.82 | CCR1 (0.37) | PDE2ALMNAPPARGAKT1IDO1 | |
| SCHEMBL1645409 | 0.82 | PDE2A (0.44) | PDE2APPARGTAS1R3TAS1R1 | |
| SCHEMBL1644460 | 0.82 | NR1H4 (0.38) | PDE2ACYP17A1LMNAPPARG | |
| SCHEMBL1643314 | 0.81 | CYP17A1 (0.39) | PDE2ACYP17A1TAS1R3TAS1R1ROCK2 | |
| SCHEMBL14378312 | 0.80 | CYP17A1 (0.36) | PDE2ACYP17A1LMNAPPARGAKT1 | |
| SCHEMBL1644704 | 0.79 | BRPF1 (0.34) | LMNAPPARGTAS1R3TAS1R1ROCK2 | |
| SCHEMBL1643362 | 0.77 | MCHR1 (0.35) | PDE2ALMNAPPARGTAS1R3TAS1R1 | |
| SCHEMBL1645220 | 0.77 | PDE2A (0.36) | PDE2ALMNAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | PDE2A 1116/4885CYP17A1 4396/4885LMNA 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.